Abstract
Statement on Seasonal Influenza Vaccine for 2011-2012: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.
Highlights
I.1 Overview and Summary of ChangesThe purpose of this statement is to provide the NACI recommendations for immunization with seasonal influenza vaccine for the 2011-2012 season, based on evidence available at this time.The seasonal trivalent vaccine for 2011-2012 contains the same three components as the 2010-2011 vaccine
Influenza is a respiratory infection caused by influenza A and B viruses and occurs in Canada every year, generally during late fall and the winter months
The eighth product (FluMist®) is a live attenuated influenza vaccine (LAIV) that is authorized for use from 2-59 years of age
Summary
The purpose of this statement is to provide the NACI recommendations for immunization with seasonal influenza vaccine for the 2011-2012 season, based on evidence available at this time. The special considerations category from the 20102011 statement has been removed (including children 2 to 4 years of age) as it is felt that elevated pandemic-related risk no longer exists for the groups in this category. Two of the groups (persons with morbid obesity and Aboriginal peoples) that NACI identified for special consideration for influenza vaccine in 2010-2011 have been added to the list of high-risk recipients for ongoing annual vaccination. Another major change in the statement is the advice for persons with egg allergy. Data are not currently available to support this recommendation for LAIV
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
